Australia markets closed

Medical Marijuana, Inc. (MJNA)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
0.0309+0.0003 (+0.98%)
At close: 3:59PM EST
Full screen
Trade prices are not sourced from all markets
Previous close0.0306
Open0.0310
Bid0.0000 x 0
Ask0.0000 x 0
Day's range0.0290 - 0.0340
52-week range0.0100 - 0.0400
Volume47,138,100
Avg. volume29,205,188
Market cap57.041M
Beta (5Y monthly)0.11
PE ratio (TTM)15.45
EPS (TTM)0.0020
Earnings date17 Nov 2020
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Medical Marijuana, Inc. CEO Honored as 2020 Best Business Leader in the United States by Global Brands Magazine
    GlobeNewswire

    Medical Marijuana, Inc. CEO Honored as 2020 Best Business Leader in the United States by Global Brands Magazine

    MJNA Medical Marijuana, Inc. CEO Honored as 2020 Best Business Leader in the United States by Global Brands Magazine SAN DIEGO, CA, Jan. 19, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that its CEO Dr. Stuart Titus has been named the winner of the 2020 Best Business Leader in the United States by Global Brands Magazine. The Global Brand Awards is an annual awards program held by Global Brands Magazine (GBM), headquartered in the UK. Each year, GBM conducts a series of awards for companies that have stood out among industry leaders, demonstrating exceptional service and unique vision. This is the eighth edition of the awards. Dr. Titus is a pioneer of the cannabis industry with more than 10 years of experience within the hemp and cannabidiol (CBD) space. He oversees a robust portfolio of subsidiary and investment companies and through his leadership, Medical Marijuana, Inc. became the first company to develop hemp-based CBD products. Dr. Titus personally helped lead and win legal battles for the importation of CBD into several countries such as Mexico, Brazil, Paraguay, Argentina and many European nations. He has also offered testimony about the safety and wellness benefits of CBD to regulatory agencies in the US, including to the FDA. “While I am certainly honored to receive this award, I want to thank my team of extremely hard-working executives who have helped me take the company to where it is today,” said Medical Marijuana, Inc. CEO Dr. Stuart Titus. “When I became involved with the company, I could have never imagined the growth and prosperity that we have achieved over the past several years. It has been a pleasure to see Medical Marijuana, Inc. become a leader in cannabis and CBD and I look forward to witnessing the entire industry prosper in the years to come.” To view the list of 2020 Global Brands Magazine award winners, visit https://www.globalbrandsmagazine.com/award-winners-2020/ and search under “Leadership Awards.” About Medical Marijuana, Inc. We are a company of firsts®. Medical Marijuana, Inc. (MJNA) is a cannabis company with three distinct business units in the non-psychoactive cannabinoid space: a global portfolio of cannabinoid-based nutraceutical brands led by Kannaway® and HempMeds®; a pioneer in sourcing the highest-quality legal non-psychoactive cannabis products derived from industrial hemp; and a cannabinoid-based clinical research and botanical drug development sector led by its pharmaceutical investment companies and partners including AXIM® Biotechnologies, Inc. and Neuropathix, Inc. Medical Marijuana, Inc. was named a top CBD producer by CNBC. Medical Marijuana, Inc. was also the first company to receive historic import permits for CBD products from the governments of Brazil, Mexico, Argentina, and Paraguay and is a leader in the development of international markets. The company’s flagship product Real Scientific Hemp Oil has been used in several successful clinical studies throughout Mexico and Brazil to understand its safety and efficacy. Medical Marijuana, Inc.’s headquarters is in San Diego, California, and additional information is available at OTCMarkets.com or by visiting www.medicalmarijuanainc.com. To see Medical Marijuana, Inc.’s corporate video, click here. Shareholders and consumers are also encouraged to buy CBD oil and other products at Medical Marijuana, Inc.’s shop. FORWARD-LOOKING DISCLAIMER This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein. FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. LEGAL DISCLOSURE Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act. CONTACT: Public Relations Contact: Kathryn Brown Account Supervisor CMW Media P. 858-264-6600 kathryn@cmwmedia.com www.cmwmedia.com Investor Relations Contact: P. (858) 283-4016 Investors@medicalmarijuanainc.com Attachment MJNA

  • Medical Marijuana, Inc. Subsidiary HempMeds® Broadens Offerings to Include CBN and CBG as Part of Company’s Updated Brand Strategy
    GlobeNewswire

    Medical Marijuana, Inc. Subsidiary HempMeds® Broadens Offerings to Include CBN and CBG as Part of Company’s Updated Brand Strategy

    MJNA Medical Marijuana, Inc. Subsidiary HempMeds® Broadens Offerings to Include CBN and CBGSAN DIEGO, CA, Jan. 05, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire \-- Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that its subsidiary HempMeds® has launched its first-ever products containing cannabigerol (CBG) and cannabinol (CBN) as part of the Company’s recently updated brand strategy. “When we founded HempMeds a decade ago, we were helping to create the entire CBD category. Since then, CBD has become the booming industry that we expected and acceptance for cannabinoids has come an incredibly long way in the last few years,” said HempMeds® Co-Founder Michelle Sides. “While our flagship RSHO products remain popular, we recognized it was time to expand alongside the industry and broaden our offerings as part of the company’s exciting new direction. We are confident that consumers will be excited about our new CBG and CBN products.”Each 12-ounce bottle of HempMeds®’ RSHO® Calm Support is formulated to promote overall relaxation with 300 mg of CBN, 2,000 mg of CBD and 300 mg of Piperine, naturally derived from black pepper, to increase bioavailability. For those looking for an additional boost of focus, each 12-ounce bottle of RSHO® Focus Support offers 1,500 mg of CBD, 1,500 mg of CBG and 300 mg of Piperine. “It is amazing to think that there are over 100 lesser-known minor cannabinoids in the cannabis plant, each with its own potential benefits. With minor cannabinoids like CBG and CBN growing in popularity, they will likely take over more and more of the expected $47.2 billion global cannabis market. We look forward to continuing to expand and evolve our offerings in response to consumer demand, starting with these new products,” said HempMeds® CEO Raul Elizalde.To learn more about these products and/or purchase them, please visit https://hempmedspx.com/shop/.About HempMeds®Founded in 2012, HempMeds® was the first company to bring hemp-based cannabidiol (CBD) oil products to market in the U.S. As a subsidiary of Medical Marijuana, Inc., HempMeds is the exclusive distributor for premium brands including Real Scientific Hemp Oil™ and Dixie Botanicals®, and operates in all 50 states and 40 countries. HempMeds® is the only company to have its CBD products listed in the Prescribers’ Digital Reference (PDR), the only company invited to speak to the World Health Organization and FDA on the benefits of CBD, and one of the first to be certified by the U.S. Hemp Authority. To learn more, please visit www.hempmedspx.com.About Medical Marijuana, Inc.We are a company of firsts®. Medical Marijuana, Inc. (MJNA) is a cannabis company with three distinct business units in the non-psychoactive cannabinoid space: a global portfolio of cannabinoid-based nutraceutical brands led by Kannaway® and HempMeds®; a pioneer in sourcing the highest-quality legal non-psychoactive cannabis products derived from industrial hemp; and a cannabinoid-based clinical research and botanical drug development sector led by its pharmaceutical investment companies and partners including AXIM® Biotechnologies, Inc. and Neuropathix, Inc. Medical Marijuana, Inc. was named a top CBD producer by CNBC. Medical Marijuana, Inc. was also the first company to receive historic import permits for CBD products from the governments of Brazil, Mexico, Argentina, and Paraguay and is a leader in the development of international markets. The company’s flagship product Real Scientific Hemp Oil has been used in several successful clinical studies throughout Mexico and Brazil to understand its safety and efficacy. Medical Marijuana, Inc.’s headquarters is in San Diego, California, and additional information is available at OTCMarkets.com or by visiting www.medicalmarijuanainc.com. To see Medical Marijuana, Inc.’s corporate video, click here.Shareholders and consumers are also encouraged to buy CBD oil and other products at Medical Marijuana, Inc.’s shop.FORWARD-LOOKING DISCLAIMERThis press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSUREThese statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.LEGAL DISCLOSUREMedical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act.CONTACT:Public Relations Contact: Kathryn Brown Account Supervisor CMW Media P. 858-264-6600 kathryn@cmwmedia.com www.cmwmedia.comInvestor Relations Contact: P. (858) 283-4016 Investors@medicalmarijuanainc.comAttachment * MJNA

  • Medical Marijuana, Inc. Subsidiary HempMeds® Announces Updated Branding Strategy to Accompany Change in Executive Leadership
    GlobeNewswire

    Medical Marijuana, Inc. Subsidiary HempMeds® Announces Updated Branding Strategy to Accompany Change in Executive Leadership

    MJNA Medical Marijuana, Inc. Subsidiary HempMeds® Announces Updated Branding StrategySAN DIEGO, Dec. 15, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire \-- Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world's first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that its subsidiary HempMeds® has launched the rebranding of its globally recognized hemp-derived cannabidiol (CBD) products as part of its recent shift in consumer strategy and executive leadership. “As the CBD industry continues to expand exponentially throughout the world, especially in the US and Latin America, we saw an opportunity to further leverage Raul Elizalde's tremendous experience in the CBD industry by positioning him as the sole CEO of HempMeds. This is an exciting new direction for the Company which comes with new initiatives and activities such as updated branding, new products and digital events in 2021,” said HempMeds® Co-Founder Michelle Sides. “We are confident that consumers will respond positively to the new HempMeds branding as we continue pushing the industry forward as have since founding the company to help trailblaze the CBD market many years ago.”The HempMeds® rebranding includes a new website, updated Company logos, new product formulations and refreshed packaging that aim to serve as more consumer-friendly, easy to understand and appeal to a wide audience. As part of the rebranding, the Company will be reformulating its RSHO® product line, which helped launch the global CBD industry, for increased absorption. The Company is also revealing two new products, one containing cannabigerol (CBG) and one containing cannabinol (CBN). The new products will expand the Company’s cannabinoid offerings and appeal to consumers’ changing demand.“After many years of fighting for broadened access to CBD around the globe, cannabinoids have finally been accepted into mainstream culture in the U.S. and other countries around the world,” said HempMeds® CEO Raul Elizalde. “With this rebranding, we aim to show that we are constantly changing to match the world’s shift toward CBD and that our products are meant for use by all consumers while maintaining our high quality.”Additionally, HempMeds® is in the process of selecting highly respected professionals for its Medical Advisory Board, which will aid in advising the Company’s expansion.View the updated HempMeds® website at https://hempmedspx.com/ and shop the entire line of HempMeds®’s newly rebranded products at https://hempmedspx.com/cbd-oil-products/.About HempMeds®Founded in 2012, HempMeds® was the first company to bring hemp-based cannabidiol (CBD) oil products to market in the U.S. As a subsidiary of Medical Marijuana, Inc., HempMeds is the exclusive distributor for premium brands including Real Scientific Hemp Oil™ and Dixie Botanicals®, and operates in all 50 states and 40 countries. HempMeds® is the only company to have its CBD products listed in the Prescribers’ Digital Reference (PDR), the only company invited to speak to the World Health Organization and FDA on the benefits of CBD, and one of the first to be certified by the U.S. Hemp Authority. To learn more, please visit www.hempmedspx.com.About Medical Marijuana, Inc.We are a company of firsts®. Medical Marijuana, Inc. (MJNA) is a cannabis company with three distinct business units in the non-psychoactive cannabinoid space: a global portfolio of cannabinoid-based nutraceutical brands led by Kannaway® and HempMeds®; a pioneer in sourcing the highest-quality legal non-psychoactive cannabis products derived from industrial hemp; and a cannabinoid-based clinical research and botanical drug development sector led by its internal R&D and scientific team and its pharmaceutical investment companies and partners including AXIM® Biotechnologies, Inc. and Neuropathix, Inc. Medical Marijuana, Inc. was named a top CBD producer by CNBC. Medical Marijuana, Inc. was also the first company to receive historic import permits for CBD products from the governments of Brazil, Mexico, Argentina, and Paraguay and is a leader in the development of international markets. Medical Marijuana, Inc.’s headquarters is in San Diego, California, and additional information is available at OTCMarkets.com or by visiting www.medicalmarijuanainc.com.To see Medical Marijuana, Inc.'s corporate video, click here.Shareholders and consumers are also encouraged to buy CBD oil and other products at Medical Marijuana, Inc.'s shop. FORWARD-LOOKING DISCLAIMERThis press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSUREThese statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.LEGAL DISCLOSUREMedical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). These companies do grow, sell, and distribute hemp-based products and are involved with the federally legal distribution of medical marijuana-based products within certain international markets. Cannabidiol is a natural constituent of hemp oil.CONTACT:Public Relations Contact:Kathryn BrownAccount SupervisorCMW MediaP. 858-264-6600kathryn@cmwmedia.comwww.cmwmedia.comInvestor Relations Contact:P. (858) 283-4016Investors@medicalmarijuanainc.comAttachment * MJNA